Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...
The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
Image 1. Inactivation of a DNA repair gene called FANCM enhances the formation of DNA damage and chromosomal instability induced by a PARP inhibitor, leading to massive cancer cell death. A research ...
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
Please provide your email address to receive an email when new articles are posted on . Nearly half of men with metastatic castration-resistant prostate cancer eligible for PARP inhibitors do not get ...
7don MSN
T cells gain superior memory through new reprogramming method, boosting cancer-fighting abilities
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback